Antiretroviral treatment of adult HIV infection: 2012 Recommendations of the International Antiviral Society-USA panel

JAMA

Volumn 308, Issue 4, 2012, Pages 387-402

  Thompson, Melanie A ^a   Aberg, Judith A ^b   Hoy, Jennifer F ^d   Telenti, Amalio ^e   Benson, Constance ^f   Cahn, Pedro ^h   Eron, Joseph J ⁱ   Günthard, Huldrych F ^j   Hammer, Scott M ^c   Reiss, Peter ^k   Richman, Douglas D ^f,g   Rizzardini, Giuliano ^l   Thomas, David L ^m   Jacobsen, Donna M ⁿ   Volberding, Paul A ^o  

^a AIDS Research Consortium of Atlanta   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

^d ALFRED HOSPITAL   (Australia)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^h UNIVERSIDAD DE BUENOS AIRES   (Argentina)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k UNIVERSITY OF AMSTERDAM   (Netherlands)

^l UNIVERSITY OF MILAN   (Italy)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ International Antiviral Society USA   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; COBICISTAT; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; FLUCONAZOLE; FOSAMPRENAVIR; LOPINAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFABUTIN; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ABNORMAL DREAMING; ACUTE HEART INFARCTION; AGE; ANEMIA; BONE DENSITY; CD4 LYMPHOCYTE COUNT; COMORBIDITY; CREATININE BLOOD LEVEL; CRYPTOCOCCAL MENINGITIS; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; ERYTHROCYTE SEDIMENTATION RATE; FOOD; FOOD DRUG INTERACTION; HEADACHE; HEALTH CARE QUALITY; HEPATITIS B; HEPATITIS C; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; INFECTION PREVENTION; KIDNEY DYSFUNCTION; KIDNEY INJURY; LIPOATROPHY; LIVER CIRRHOSIS; LIVER TOXICITY; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SELECTION; PR INTERVAL; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SLEEP DISORDER; SYSTEMATIC REVIEW; TREATMENT PLANNING; VIRUS LOAD; VIRUS RESISTANCE;

EID: 84864131448     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.7961     Document Type: Review

References (146)

1. Joint United Nations Programme on HIV/AIDS. Progress Report Summary 2011: Global HIV/AIDS Response. http://www.unaids.org/en/media/unaids/contentassets/ documents/unaidspublication/2011/20111130-UA-Report-en.pdf. Accessed April 2, 2012.
2. Cohen MS, Chen YQ, McCauley M, et al HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
3. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in menwho have sex with men. N Engl J Med. 2010;363(27):2587-2599.
4. Baeten J. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. Abstract presented at: Sixth IAS Conference on HIV Pathogenesis, Treatment, and Prevention; July 17-20, 2011; Rome, Italy. Abstract MOAX0106.
5. Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. Abstract presented at: Sixth IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 17-20, 2011; Rome, Italy. Abstract WELBC01.
6. The White House Office of the Press Secretary. Fact sheet: the beginning of the end of AIDS. http://www.whitehouse.gov/the-press-office/2011/12/01/fact- sheet-beginning-end-aids. Accessed April 2, 2012.
7. Thompson MA, Aberg JA, Cahn P, et al International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321-333.
8. Carpenter CCJ, Fischl MA, Hammer SM, et al International AIDS Society-USA. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA. 1996;276(2):146-154.
9. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817-833.
10. Cain LE, Logan R, Robins JM, et al HIV-CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 2011;154(8):509-515.
11. Jonsson M, Fusco JS, et al Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med. 2011;171(17):1560-1569.
12. Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012;9(3):e1001194.
13. Maman D, Pujades-Rodriguez M, Nicholas S, et al. Response to antiretroviral therapy in sub-Saharan Africa: improved survival associated with CD4 above 500 cells/μL [published online March 23, 2012]. AIDS. doi:10.1097/QAD.0b013e328352d054.
14. van Lelyveld SF, Gras L, Kesselring A, et al ATHENA National Observational Cohort Study. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS. 2012;26(4):465-474.
15. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2551-2559.
16. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health. 2012;12(1):234.
17. + T-cell counts and cardiovascular risk in treated HIV disease. AIDS. 2012;26(9):1115-1120.
18. Seaberg EC, Benning L, Sharrett AR, et al. Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke. 2010;41(10):2163-2170.
19. Hughes JP, Baeten JM, Lingappa JR, et al Partners in Prevention HSV/HIV Transmission Study Team. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis. 2012;205(3):358-365.
20. Rieder P, Joos B, von Wyl V, et al Swiss HIV Cohort Study. HIV-1 transmission after cessation of early antiretroviral therapy among men having sexwith men. AIDS. 2010;24(8):1177-1183.
21. Politch JA, Mayer KH, Welles SL, et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men [published online March 23, 2012]. AIDS. doi:10.1097/QAD.0b013e328353b11b.
22. Lambers FA, Prins M, Thomas X, et al MOSAIC (MSM Observational Study of Acute Infection With Hepatitis C) study group. Alarming incidence of hepatitis C virus reinfection after treatment of sexually acquired acute hepatitis C virus infection in HIVinfected MSM. AIDS. 2011;25(17):F21-F27.
23. Centers for Disease Control and Prevention. Sexually Transmitted Disease: Surveillance 2010. http://www.cdc.gov/std/stats10/surv2010.pdf. Accessed April 2, 2012.
24. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532-539.
25. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):e11068.
26. Lee NM, Saha S. Nausea and vomiting of pregnancy. Gastroenterol Clin North Am. 2011;40(2):309-334.
27. Bardeguez AD, Lindsey JC, Shannon M, et al PACTG 1025 Protocol Team. Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr. 2008;48(4):408-417.
28. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4(5):e5575.
29. Geng EH, Kahn JS, Chang OC, et al. The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation. Clin Infect Dis. 2011;53(10):1008-1014.
30. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early vs delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. Clin Infect Dis. 2010;50(11):1532-1538.
31. National Institute of Allergy and Infectious Diseases. HIV treatment study in patients with cryptococcal meningitis ends enrollment early. May 30, 2012. http://www.niaid.nih.gov/news/newsreleases/2012/Pages/COAT.aspx. Accessed June 1, 2012.
32. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365(16):1492-1501.
33. Blanc FX, Sok T, Laureillard D, et al CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Earlier vs later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471-1481.
34. Havlir DV, Kendall MA, Ive P, et al; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482-1491.
35. Török ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374-1383.
36. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis. 2009;48(12):1763-1771.
37. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007;21(16):2209-2216. (Pubitemid 350287219)
38. Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362(9397):1708-1713. (Pubitemid 37468321)
39. Wearne N, Swanepoel CR, Boulle A, Duffield MS, Rayner BL. The spectrum of renal histologies seen in HIV with outcomes, prognostic indicators and clinical correlations [published online February 7, 2012]. Nephrol Dial Transplant. doi:10.1093/ndt/gfr702.
40. Lescure FX, Flateau C, Pacanowski J, et al. HIV-associated kidney glomerular diseases: changes with time and HAART. Nephrol Dial Transplant. 2012;27(6):2349-2355.
41. Zeng M, Southern PJ, Reilly CS, et al. Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog. 2012;8(1):e1002437.
42. Gianella S, von Wyl V, Fischer M, et al Swiss HIV Cohort Study. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther. 2011;16(4):535-545.
43. Wyl Vv, Gianella S, Fischer M, et al; Swiss HIV Cohort Study. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One. 2011;6(11):e27463.
44. Grijsen ML, Steingrover R, Wit FWNM,et al Primo-SHM Study Group. No treatment vs 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med. 2012;9(3):e1001196.
45. Hogan CM, Degruttola V, Sun X, et al; A5217 Study Team. The setpoint study (ACTG A5217): effect of immediate vs deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012;205(1):87-96.
46. Brenner BG, Roger M, Stephens D, et al Montreal PHI Cohort Study Group. Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis. 2011;204(7):1115-1119.
47. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet. 2011;378(9787):256- 268.
48. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198(5):687-693.
49. Hasse B, Ledergerber B, Furrer H, et al Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53(11):1130-1139.
50. Krentz HB, Cosman I, Lee K, Ming JM, Gill MJ. Pill burden in HIV infection: 20 years of experience. Antivir Ther. 2012.
51. Marzolini C, Back D, Weber R, et al Swiss HIV Cohort Study Members. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011;66(9):2107-2111.
52. Llibre JM, Arribas JR, Domingo P, et al Spanish Group for FDAC Evaluation. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS. 2011;25(14):1683-1690.
53. Scherrer AU, Ledergerber B, von Wyl V, et al Swiss HIV Cohort Study. Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis. 2011;53(11):1143-1152.
54. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7(2):e31591.
55. Young J, Schäfer J, Fux CA, et al Swiss HIV Cohort Study. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS. 2012;26(5):567-575.
56. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867-875.
57. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40(11):1559-1585. (Pubitemid 40720806)
58. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791-1801.
59. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825-831.
60. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201(3):318-330.
61. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011;25(10):1289-1298.
62. Lang S, Mary-Krause M, Cotte L, et al Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170:1228-1238.
63. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53(1):84-91.
64. Ribaudo HJ, Benson CA, Zheng Y, et al; ACTG A5001/ALLRT Protocol Team. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short- and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011;52(7):929-940.
65. US Food and Drug Administration. FDA drug safety communication: safety review update of abacavir and possible increased risk of heart attack. March 1, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm245164.htm. Accessed March 26, 2012.
66. Smith KY, Patel P, Fine D, et al HEAT Study Team. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23(12):1547-1556.
67. Kenedi CA, Goforth HW. A systematic review of the psychiatric side effects of efavirenz. AIDS Behav. 2011;15(8):1803-1818.
68. Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM; A5097s Study Team. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2009;10(6):343-355.
69. Gathe J, Andrade-Villanueva J, Santiago S, et al. Efficacy and safety of nevirapine extended-release once daily vs nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Antivir Ther. 2011;16(5):759-769.
70. Molina JM, Cahn P, Grinsztejn B, et al; ECHO study group. Rilpivirine vs efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238-246.
71. Cohen CJ, Andrade-Villanueva J, Clotet B, et al; THRIVE study group. Rilpivirine vs efavirenz with 2 background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229-237.
72. Elion R, Cohen C, Gathe J, et al; GS-US-216-0105 Study Team. Phase 2 study of cobicistat vs ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 2011;25(15):1881-1886.
73. Soliman EZ, Lundgren JD, Roediger MP, et al INSIGHT SMART Study Group. Boosted protease inhibitors and the electrocardiographicmeasures of QT and PR durations. AIDS. 2011;25(3):367-377.
74. Mocroft A, Kirk O, Reiss P, et al; EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIVpositive patients. AIDS. 2010;24(11):1667-1678.
75. Daar ES, Tierney C, Fischl MA, et al; AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445-456.
76. Vrouenraets SM,Wit FW, Fernandez Garcia E, et al; BASIC Study Group. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naive HIV-1-infected patients. HIV Med. 2011;12(10):620-631.
77. Eron JJ Jr, Rockstroh JK, Reynes J, et al QDMRK Investigators. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial [published correction appears in Lancet Infect Dis. 2011;11(12):895]. Lancet Infect Dis. 2011;11(12):907-915.
78. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir vs co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439-2448.
79. Molina J, LaMarca A, Andrade-Villaneuva J, et al Study 145 Team. Efficacy and safety of once daily elvitegravir vs twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavirboosted protease inhibitor: ransomised, doubleblind, phase 3 non-inferiority study. Lancet Infect Dis. 2012;12(1):27-35.
80. German P, Liu HC, Warren D, et al. Effect of cobicistat on glomerular filtration rate (GFR) in subjects with normal and impaired renal function. Abstract presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2012; Chicago, IL. Abstract H2-804.
81. Vandekerckhove LP, Wensing AM, Kaiser R, et al European Consensus Group on Clinical Management of Tropism Testing. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis. 2011;11(5):394-407.
82. The Antiretroviral Pregnancy Registry. The Antiretroviral Pregnancy Registry: Interim Report. June 2012. http://www.apregistry.com/forms/interim- report.pdf. Accessed March 26, 2012.
83. d'Arminio Monforte A, Reiss P, Ryom L, et al. ATV-containing ART is not associated with an increased risk of cardio- or cerebro-vascular events in the D:A:D Study. Abstract presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA. Abstract 823.
84. Hansen AB, Gerstoft J, Kronborg G, et al. Incidence of low- and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;26(3):285-293.
85. Stellbrink HJ, Orkin C, Arribas JR, et al ASSERT Study Group. Comparison of changes in bone density and turnover with abacavir-lamivudine vs tenofoviremtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963-972.
86. Yin MT, Zhang CA, McMahon DJ, et al. Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metab. 2012;97(2):554-562.
87. López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41(9):681-690.
88. Abdool Karim S, Naidoo K, Padayatchi N, et al. Optimal timing of ART during TB therapy: findings of the SAPiT trial. Abstract presented at: 18th Conference on Retroviruses and Opportunistic Infections. February 27-March 2, 2011; Boston, MA. Abstract 39LB.
89. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother. 2006;58(6):1299-1302. (Pubitemid 44884158)
90. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300(5):530-539.
91. Zhang J, Zhu L, Stonier M, et al. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. J Antimicrob Chemother. 2011;66(9):2075-2082.
92. Naiker S, Conolly C, Weisner L, et al. Pharmacokinetic evaluation of different rifabutin dosing strategies in African TB patients on lopinavir/ritonavir-based ART. Abstract presented at: 18th Conference on Retroviruses and Opportunistic Infections. February 27-March 2, 2011; Boston, MA. Abstract 650.
93. Sekar V, Tomaka F, Lefebvre E, et al. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone. J Clin Pharmacol. 2011;51(2):271-278.
94. Brainard DM, Kassahun K, Wenning LA, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J Clin Pharmacol. 2011;51(6):943-950.
95. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009;49(9):1305-1311.
96. Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis. 2009;48(10):1471-1474.
97. Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60(48):1650-1653.
98. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med. 2007;356(25):2614-2621. (Pubitemid 46961006)
99. Thio CL. Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy. Antivir Ther. 2010;15(3 pt B):487-491.
100. Matthews GV, Manzini P, Hu Z, et al; PHIDISA II Study Team. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS. 2011;25(14):1727-1735.
101. Jacobson IM,McHutchison JG, Dusheiko G, et al ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection.NEngl J Med. 2011;364(25):2405-2416.
102. Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection.NEngl J Med. 2011;364(13):1195-1206.
103. Sulkowski M, Pol S, Cooper C, et al. Boceprevir +pegylated interferon + ribavirin for the treatment of HCV/HIV-co-infected patients: end of treatment (week-48) interim results. Abstract presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA. Abstract 47.
104. Dieterich D, Soriano V, Sherman K, et al. Telaprevir in combination with pegylated interferon-a-2a+RBV in HCV/HIV-co-infected patients: a 24-week treatment interim analysis. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA. Abstract 46.
105. Hepatitis Drug Interactions. Drug interactions charts. http://www.hep-druginteractions.org/. Accessed March 26, 2012.
106. Fulco PP, Hynicka L, Rackley D. Raltegravir-based HAART regimen in a patient with large B-cell lymphoma. Ann Pharmacother. 2010;44(2):377-382.
107. Sayana S, Javanbakht M, WeinsteinM, Khanlou H. Clinical impact and cost of laboratory monitoring need review even in resource-rich setting. J Acquir Immune Defic Syndr. 2011;56(3):e97-e98.
108. Doyle T, Smith C, Vitiello P, et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2012;54(5):724-732.
109. Maggiolo F, Callegaro A, Cologni G, et al. Ultra-sensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure [published online June 4, 2012]. J Acquir Immune Defic Syndr. doi:10.1097/QAI.0b013e3182567a57.
110. Taiwo B,Gallien S, Aga E, et al. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis. 2011;204(4):515-520.
111. von Wyl V, Yerly S, Böni J, et al Swiss HIV Cohort Study. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis. 2012;54(1):131-140.
112. Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM. Design issues in initial HIV-treatment trials: focus on ACTG A5095. Antivir Ther. 2006;11(6):751-760. (Pubitemid 44497170)
113. Doyle T, Geretti AM. Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis. 2012;25(1):17-25.
114. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev. 2012;14(1):17-27.
115. Wittkop L, Günthard HF, de Wolf F, et al; EuroCoord-CHAIN Study Group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363-371.
116. Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drugdrug interactions. Curr Opin HIV AIDS. 2011;6(6):514-526.
117. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012;11(2):179-185.
118. Ford MA, Spicer CM. Monitoring HIV Care in the United States: Indicators and Data Systems. Washington, DC: National Academies Press; 2012.
119. Wandeler G, Keiser O, Hirschel B, et al Swiss HIV Cohort Study. A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS One. 2011;6(12):e27903.
120. Sangsari S, Milloy MJ, Ibrahim A, et al. Physician experience and rates of plasma HIV-1 RNA suppression among illicit drug users: an observational study. BMC Infect Dis. 2012;12:22.
121. Madruga JV, Berger D, McMurchieM, et al; TITAN study group. Efficacy and safety of darunavirritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370(9581):49-58. (Pubitemid 47023100)
122. Trottier B, Di Perri G, Madruga JV, et al. Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2. HIV Clin Trials. 2010;11(4):175-185.
123. Scherrer AU, von Wyl V, Böni J, et al Swiss HIV Cohort Study. Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2011;57(1):24-31.
124. Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011;204(11):1811-1815.
125. Holodniy M, Brown ST, Cameron DW, et al OPTIMA Team. Results of antiretroviral treatment interruption and intensification in advanced multidrug resistant HIV infection from the OPTIMA trial. PLoS One. 2011;6(3):e14764.
126. + T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin Trials. 2010;11(6):351-358.
127. + T cell response. J Infect Dis. 2011; 203(7):960-968.
128. + T-cell response: a randomized controlled trial. J Infect Dis. 2011;204(10):1532-1540.
129. Rusconi S, Vitiello P, Adorni F, et al. Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART. J Int AIDS Soc. 2012;13(suppl 4):044.
130. Abrams D, Lévy Y, Losso MH, et al INSIGHTE-SPRIT Study Group; SILCAAT Scientific Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361(16):1548-1559.
131. Martínez E, Larrousse M, Llibre JM, et al SPIRAL Study Group. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24(11):1697-1707.
132. Eron JJ, Young B, Cooper DA, et al; SWITCHMRK 1 and 2 Investigators. Switch to a raltegravir-based regimen vs continuation of a lopinavir-ritonavir- based regimen in stableHIV-infected patientswith suppressed viraemia (SWITCHMRK 1 and 2): 2multicentre, double-blind, randomised controlled trials. Lancet. 2010;375(9712):396-407.
133. Schouten JT, Krambrink A, Ribaudo HJ, et al. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis. 2010;50(5):787-791.
134. Mills A, Cohen C, De Jesus E, et al. Switching from efavirenz/ emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single table regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumerate (FTC/RPV/TDF) STR in virologically suppressed, HIV-1 infected subjects. Abstract presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2011; Chicago, IL. Abstract H2-794c.
135. De Lazzari E, León A, Arnaiz JA, et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med. 2008;9(4):221-226. (Pubitemid 351467795)
136. Valantin MA, Bittar R, de Truchis P, et al TOTEM Trial Group. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. J Antimicrob Chemother. 2010;65(3):556-561.
137. Rasmussen TA, Tolstrup M, Melchjorsen J, et al. Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis. 2011;11:267.
138. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48(4):484-488.
139. Vispo E, Barreiro P, Maida I, et al. Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. HIV Clin Trials. 2010;11(4):197-204.
140. Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011;25(7):929-939.
141. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24(15):2365-2374.
142. Gutmann C, Cusini A, Günthard HF, et al Swiss HIV Cohort Study. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010;24(15):2347-2354.
143. Mathis S, Khanlari B, Pulido F, et al. Effectiveness of protease inhibitor monotherapy vs combination antiretroviral maintenance therapy: a meta-analysis. PLoS One. 2011;6(7):e22003.
144. Van Damme L, Corneli A, Ahmed K, et al. The FEM-PrEP trial of emtricitabine/tenofovir disoproxil fumarate (Truvada) among African women. Abstract presented at: 19th Conference on Retroviruses and Opportunistic Infections. March 5-8, 2012; Seattle, WA. Abstract 32LB.
145. Microbicide Trials Network. The VOICE study: Vaginal and Oral Interventions to Control the Epidemic. http://www.mtnstopshiv.org/news/studies/ mtn003/backgrounder. Accessed April 2, 2012.
146. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60(3):65-68.